BRD8 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of PaTu 8988t cells in which the BRD8 gene has been disrupted. The polyclonal format provides a heterogeneous loss-of-function model that preserves genetic diversity while achieving target gene ablation, enabling robust population-level studies without the biases associated with single-cell cloning. This cell pool is suitable for a broad range of experimental applications in biomedical research, including the investigation of BRD8-dependent processes in a pancreatic cancer context.
The parental PaTu 8988t cell line is a human pancreatic ductal adenocarcinoma (PDAC) line derived from a liver metastasis of a primary pancreatic adenocarcinoma. As a model of metastatic pancreatic cancer, PaTu 8988t cells recapitulate key hallmarks of aggressive disease, including rapid proliferation, invasive capacity, and altered DNA damage responses. These characteristics provide a clinically relevant platform for investigating molecular drivers of PDAC metastasis and for evaluating therapeutic vulnerabilities.
BRD8 serves as a scaffolding subunit of the NuA4/TIP60 histone acetyltransferase complex, where it coordinates histone H4 acetylation to regulate chromatin structure and transcription. The complex is activated by upstream ATM/ATR kinases and TP53 in response to DNA damage, and it interfaces with E2F transcription factors during cell cycle progression. BRD8 directly interacts with core NuA4 components including TRRAP, TIP60/KAT5, EPC1, ING3, and MORF4L1, and it functionally crosstalks with SWI/SNF chromatin remodelers such as SMARCA4 and ARID1A. Through these interactions, BRD8 modulates the expression of downstream effectors like CDKN1A (p21), BAX, and CCND1, thereby controlling cell cycle arrest, apoptosis, and proliferation. Disruption of BRD8 impairs histone H4 acetylation, leading to defective chromatin remodeling, altered transcription of DNA repair and cell cycle genes, and increased genomic instability.
In the metastatic PaTu 8988t background, BRD8 loss offers a unique opportunity to study how chromatin regulatory defects contribute to pancreatic cancer progression. The inherent genetic alterations of these cells are likely to exacerbate DNA double-strand break repair deficiencies and dysregulate TP53- and E2F-dependent transcriptional networks upon BRD8 deletion. This model therefore enables the functional characterization of BRD8 in a metastatic context and can be used to explore its role in therapy resistance and tumor aggressiveness.
A variety of experimental approaches can be applied to characterize these polyclonal knockout cells. Western blotting and RT-qPCR can confirm BRD8 ablation and quantify expression changes of downstream targets such as CDKN1A and BAX. ChIP-qPCR allows assessment of histone H4 acetylation levels at specific loci, while ??H2AX foci assays provide a measure of DNA damage repair efficiency. Cell proliferation, survival, and migration can be evaluated using colony formation, cell viability, and scratch wound assays. Additionally, the model is suitable for drug sensitivity profiling and synthetic lethality screens. For further information, please contact Ascent Research.
